Him & Hers announced Thursday that eligible users now have access to the full line of U.S. Food and Drug Administration (FDA)-approved GLP-1 drugs on its platform.
Healthcare providers will now be able to send prescriptions for Eli Lilly’s Zepbound, Mounjaro, and oral Foundayo to LillyDirect pharmacies, giving users access to out-of-pocket pricing. The direct-to-consumer telemedicine platform began offering Wegovy tablets and injections, as well as Ozempic injections, in late March.
According to the telemedicine company’s website, here’s a breakdown of the lowest monthly out-of-pocket costs for each drug:
- Foundayo Pill: Starting at $149/month
- Munjaro: $1,899 per month
- Ozempic: Starting at $199/month
- Wegovy Pills: Starting at $149/month
- Wegovy Pens: Starting at $199/month
- Zepbound Vials: Starting at $299/month
- Zepbound KwikPen: Starting at $299/month
Interested patients can check their membership eligibility on the platform.
Users can also purchase the higher 7.2 mg dose of Wegovy injection, which the FDA approved on March 19th. This dose can also be purchased through GoodRx for $399 per month.
“Our goal is to ensure that Hims & Hers customers trust us with their health journey and have access to diverse treatment options with a comprehensive care experience,” the company said in a press release. “This is all part of giving our customers more ways to start and sustain their health journey based on their unique history, preferences, needs and goals.”
The development comes nearly a year after Novo Nordisk announced partnerships with various telemedicine companies, including Him & Hers, on the high-demand weight loss drug. Novo previously partnered with Him & Hers to sell a combination version of semaglutide, the active ingredient in Novo’s Wigovy and Ozempic drugs.
Him & Hers is also one of the companies behind Novo’s Wegovy subscription plan, the “first and only” plan of its kind that the manufacturer says can save patients up to $1,200 annually.
